MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

The minimal residual disease testing market faces various challenges. Healthcare providers are still adopting these molecular diagnostic tests due to their high cost. Additionally, lack of expertise and complex workflow processes also hinder the growth of this market. Reimbursement issues pose another challenge as many payers do not provide coverage for these advanced tests. Standardization of techniques and result interpretation remains an area that needs more research efforts.

Market Opportunities – Strategic Collaborations Between Companies and Research Institutes

Strategic collaborations between companies and research institutes could be a great opportunity in the minimal residual disease testing market. When companies partner with academic institutions and leverage their research expertise, it helps accelerate the development of novel and improved testing technologies. For instance, in June 2023, Myriad Genetics, Inc., a biotechnology company, announced a collaboration agreement with The University of Texas MD Anderson Cancer Center to support research focused on metastatic renal cell carcinoma treatment selection and response. The project will use Myriad Genetics, Inc.’s minimal residual disease (MRD) testing platform, a tumor-informed high-definition assay that detects circulating tumor DNA (ctDNA).